Avantor Inc. reported its fourth‑quarter and full‑year 2025 financial results on February 11, 2026. Net sales for the quarter fell 1.4% to $1.66 billion, while net income dropped sharply to $52 million from $500 million a year earlier. Adjusted earnings per share of $0.22 matched consensus estimates, and adjusted EBITDA reached $252 million, a 15.2% margin that is 3.0 percentage points lower than the 18.2% margin recorded in Q4 2024.
Revenue decline was driven by modest weakness in both of Avantor’s core segments. Laboratory Solutions sales slipped 0.9% to $1.12 billion, with adjusted operating income at $114 million and a 10.2% margin. Bioscience Production sales fell 2.4% to $548 million, and the segment’s operating income fell to $34 million, reflecting lower demand for high‑value reagents and increased competition. The company’s full‑year sales of $6.55 billion fell 3.4% from $6.75 billion in 2024, with Laboratory Solutions contributing $4.40 billion of the total and Bioscience Production $2.15 billion.
Margin compression was largely a result of the $785 million goodwill impairment disclosed in Q3 2025, which reduced net income to a loss of $530 million for the year. Adjusted EBITDA margin fell to 16.3% from 17.7% in 2024, while adjusted operating income margin slipped to 14.6% from 16.1%. The impairment, driven by competitive pricing pressure and the loss of key accounts, offset gains from cost‑control initiatives and a favorable mix shift toward higher‑margin products.
Management guided for 2026 with adjusted earnings per share of $0.77–$0.83, below the consensus estimate of $0.91, and projected a 15–20‑basis‑point decline in adjusted EBITDA margin. The company also reiterated its “Avantor Revival” plan, which includes a relaunch of the VWR brand, supply‑chain and e‑commerce upgrades, and a $500 million share‑repurchase program. The guidance signals a transition year marked by continued headwinds but a focus on long‑term operational efficiency.
CEO Emmanuel Ligner emphasized that the company is “moving with urgency to execute Revival and turn around performance.” He noted that the 2026 outlook reflects “purposeful investment” to strengthen the business, while acknowledging that margin compression will persist in the short term. The market reaction was muted, with investors focusing on the lower 2026 guidance and the impact of the goodwill impairment on the full‑year loss.
Overall, Avantor’s results illustrate a company in the midst of a strategic turnaround. Revenue is declining modestly, margins are compressing due to one‑time impairments and competitive pressures, but management’s disciplined cost controls and the “Avantor Revival” plan provide a framework for future improvement. Investors will likely monitor the company’s ability to execute the revival plan and restore profitability in 2027 and beyond.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.